CLLS: Cellectis S.A. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
27 institutions reported holding $28.45M of Cellectis S.A. on Form 13F (32 the quarter before). 3 opened a new position and 8 sold out. Shares held by institutions: -7%.
| Largest holders | Shares | Value |
|---|---|---|
| B Group, Inc. | 3,281,501 | $9.84M |
| Long Focus Capital Management, LLC | 2,741,853 | $8.23M |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2,644,881 | $7.93M |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 226,875 | $681K |
| BlackRock, Inc. | 225,444 | $676K |
| MORGAN STANLEY | 85,455 | $256K |
| LPL Financial LLC | 84,415 | $253K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 50,453 | $151K |
| BNP PARIBAS FINANCIAL MARKETS | 40,100 | $120K |
| UBS Group AG | 33,926 | $102K |
Clinical trial readouts
1 Phase 2 or 3 trials by Cellectis S.A. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-08 (est.) | UCART20x22 | B-cell Non-Hodgkin Lymphoma (B-NHL) | Phase 1/2 | 80 | Recruiting | NCT05607420 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.